GLP-1 receptor agonists have become some of the most prescribed medications in modern medicine. Originally developed for type 2 diabetes, drugs like semaglutide and tirzepatide are now reshaping the treatment of obesity, cardiovascular disease, and beyond. But as millions of patients start, and stay on, these medications, a critical question is emerging: What happens to their bones? 

The answer, it turns out, depends entirely on who the patient is. 

Two Populations, Two Very Different Stories 

Here's the paradox at the heart of this topic: GLP-1 RAs appear to help bones in patients with type 2 diabetes, but may hurt them in patients using these drugs primarily for weight loss.^1-3 

In diabetes, the data are encouraging. A systematic review of 25 studies found that GLP-1 RAs significantly improved bone mineral density (BMD) at the lumbar spine (+0.07 g/cm²), hip neck (+0.05 g/cm²), and total hip (+0.06 g/cm²) compared to controls.¹ A second meta-analysis confirmed these results and showed favorable shifts in bone turnover markers: more formation, and less resorption.⁴ 

However, strip away the diabetes diagnosis, and the picture flips. A retrospective study of patients on semaglutide or tirzepatide without diabetes found greater total hip bone loss compared to matched controls (-1% vs -0.6%).³ In patients with diabetes, bone loss was comparable between groups. The culprit? Weight loss itself. The magnitude of weight loss directly correlated with bone loss at weight-bearing sites.³ 

A narrative review of clinical studies reinforced this pattern: BMD reductions with GLP-1 RAs are most pronounced at skeletal sites under high mechanical loading like the femur and tibia, and track closely with how much weight a patient loses.² 

The Weight Loss Problem (and Its Solution) 

This isn't entirely surprising. Bone is constantly adapting to the demands placed upon it. When someone loses 15-20% of their body weight, the skeleton no longer has to bear the same load. As a result, bone density can decline — particularly at the hip. 

But here's the good news: exercise appears to reverse the trend. 

A randomized trial compared four groups: placebo, exercise alone, liraglutide alone, and liraglutide plus exercise. The combination group lost the most weight (approximately 17 kg) yet preserved BMD at both the hip and spine. Liraglutide alone, by contrast, led to significant decreases at both sites.⁵ 

The takeaway is clear: for patients on GLP-1 RAs who are losing substantial weight, exercise isn't optional, it's the insurance policy protecting their muscle and bone. 

Where Hormones Fit In: Menopause, Estrogen, and Bone 

For midlife and older women, GLP-1-associated weight loss does not happen in a hormonal vacuum. Estrogen is one of the central regulators of bone remodeling. As estrogen declines during the menopausal transition, bone resorption accelerates, particularly in the early postmenopausal years. This matters because many patients seeking GLP-1 therapy for weight management are also in perimenopause or postmenopause, when baseline skeletal vulnerability may already be increasing.^6-8 

For these patients, bone protection should include more than DEXA timing and calcium intake. Clinicians should assess menopausal status, vasomotor and genitourinary symptoms, fracture history, early menopause or oophorectomy, family history, medications, thyroid status, vitamin D status, protein intake, and resistance-training habits. Hormone testing can be useful when the diagnosis is unclear, when premature ovarian insufficiency or early menopause is suspected, or when therapy monitoring is clinically indicated.^9-10 

Menopausal hormone therapy has been shown to prevent bone loss and reduce fracture risk, and it may be an appropriate option for selected symptomatic women, especially those younger than 60 or within 10 years of menopause onset who do not have contraindications.^6-7  

The practical point is not that every woman on a GLP-1 RA needs hormone therapy. Rather, clinicians should not miss untreated estrogen deficiency, early menopause, or menopause-related bone loss when evaluating skeletal risk. For the right patient, hormone therapy, resistance training, adequate protein, calcium and vitamin D, and fall-risk reduction can work together as part of a bone-preservation strategy during medically assisted weight loss. 

Fracture Risk: The Outcome That Matters Most 

BMD is a surrogate. What clinicians really want to know is: do these patients break more bones? 

For patients with type 2 diabetes, the answer is reassuringly no — and possibly the opposite. A meta-analysis of 44 RCTs involving nearly 48,000 patients found a modest but statistically significant 23% reduction in fracture risk overall (RR 0.77, 95% CI 0.61-0.96).¹¹ An earlier meta-analysis of 38 trials reported similar findings (OR 0.71, 95% CI 0.56-0.91).¹² 

Two important nuances emerged from these analyses: 

• Duration of treatment matters. Fracture protection only became significant after 52-78 weeks of treatment.^11-12 
• Not all agents are created equal. Liraglutide and lixisenatide showed the most consistent fracture risk reduction.^11-12 

A large cohort study added further support, finding that GLP-1 RA use was associated with significantly lower risks of vertebral compression fractures and related surgical interventions in patients with type 2 diabetes.¹³ 

However, there's a caveat for older patients. A population-based study of over 46,000 adults aged 65 and older with type 2 diabetes found an 11% increased fracture risk with GLP-1 RA initiation compared to SGLT2 inhibitors or DPP-4 inhibitors (HR 1.11, 95% CI 1.01-1.21).¹⁴ Whether this reflects a direct effect of the medications, the weight loss they produce, or other confounding factors remains unclear, but it's a signal worth paying attention to in a population already more vulnerable for falls and fractures. 

This signal is particularly relevant for older postmenopausal women, who may have overlapping risks: age-related bone loss, estrogen deficiency, sarcopenia, fall risk, and medication-associated weight loss. 

How GLP-1 RAs Affect Bone: The Mechanisms 

The biology is complex and, frankly, contradictory depending on whether the data come from a petri dish, animal model, or a patient. 

In vitro and animal studies paint a bone-friendly picture: GLP-1 RAs promote osteoblast differentiation, inhibit osteoclast activity, decrease sclerostin expression (unlocking the Wnt/β-catenin bone formation pathway), and stimulate calcitonin release from thyroid C cells.¹⁵ They also appear to modulate the RANKL/OPG signaling axis in favor of bone preservation.^13-15 

In humans, however, the dominant signal is increased bone resorption (elevated CTX levels), with a more modest increase in bone formation markers.² 

The net effect likely depends on whether the metabolic benefits of the drug — improved insulin sensitivity, reduced inflammation, better calcium and phosphate handling — outweigh the mechanical unloading from weight loss.¹³ 

In women, the hormonal environment adds another layer. Estrogen deficiency increases osteoclast-driven bone resorption, while estrogen therapy can reduce bone turnover and preserve BMD in appropriately selected postmenopausal patients.^6-8 This means the same degree of GLP-1-associated weight loss may carry different skeletal implications in a 38-year-old premenopausal woman, a 52-year-old in late perimenopause, and a 68-year-old postmenopausal woman with osteopenia. 

What the Guidelines Say 

The American Diabetes Association's 2026 Standards of Care note that GLP-1 RAs at lower doses are likely neutral to beneficial for BMD and fracture risk. However, the guidelines acknowledge a critical gap: data is lacking for the higher doses commonly used for weight management. In these settings, where weight loss is often more rapid and pronounced, there may be counterbalancing skeletal risks that are not yet well defined.¹⁶ 

Practical Recommendations for Clinicians 

Given the current evidence, a few principles can guide clinical decision-making: 

• Prescribe exercise alongside GLP-1 RAs. This is the single most actionable intervention. Resistance training and weight-bearing exercise can preserve BMD even during significant weight loss. 
• Assess menopausal and hormonal context. In perimenopausal and postmenopausal women, ask about menopause timing, vasomotor symptoms, genitourinary symptoms, early menopause, oophorectomy, prior hormone therapy, contraindications, and fracture risk. 
• Consider menopausal hormone therapy when appropriate. For selected symptomatic women, hormone therapy may help preserve bone while also treating menopausal symptoms. It should be individualized and periodically reassessed. 
• Weigh skeletal risk more carefully in higher-risk groups. Patients without diabetes, older adults, postmenopausal women, those with early menopause, low BMI, substantial weight loss, osteoporosis, prior fracture, glucocorticoid exposure, or fall risk warrant closer monitoring. 
• Consider baseline and follow-up DEXA scans in high-risk patients, particularly those on higher doses for weight management. 
• Optimize the basics. Adequate dietary protein, calcium, vitamin D, fall prevention strategies, and attention to modifiable fracture risk factors remain essential. 
• Think/treat long-term. In patients with diabetes, the fracture-protective effects of GLP-1 RAs appear to require at least a year of treatment to manifest. In weight-loss populations, bone preservation depends on actively managing the mechanical, nutritional, muscular, and hormonal consequences of weight reduction. 

The Bottom Line 

GLP-1 receptor agonists are not inherently bad for bone, but they're not uniformly good either. In patients with type 2 diabetes, the skeletal effects are generally favorable, with improved BMD and reduced fracture risk over time. In patients without diabetes who are losing significant weight, bone loss at weight-bearing sites is a real concern that may be mitigated with exercise. 

For midlife and older women, the equation is even more nuanced. Menopause-related estrogen decline, sarcopenia, fall risk, and rapid weight loss can converge on the skeleton at the same time. This is why clinicians should evaluate menopausal status and hormone context alongside the usual bone-health variables. 

As these medications become a cornerstone of metabolic medicine, bone health cannot be neglected. The evidence is clear enough to warrant action: assess risk, prescribe exercise, protect lean mass with adequate dietary protein, optimize calcium and vitamin D, evaluate menopausal and hormonal context, monitor when appropriate, and individualize care. The skeleton deserves the same attention as the scale. 

References

1. Tan Y, Liu S, Tang Q. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol. 2025;62(5):589-606. doi:10.1007/s00592-025-02468-5 
2. Al Refaie A, Baldassini L, Mondillo C, et al. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes mellitus: friends or foes to bone health? a narrative review of clinical studies. Endocrine. 2025;89(1):30-38. doi:10.1007/s12020-025-04253-4 
3. Liu Y, Walzer D, Schmitz S, et al. Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures. J Clin Endocrinol Metab. Published online February 7, 2026. doi:10.1210/clinem/dgag052 
4. Li X, Li Y, Lei C. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Metabolism in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Int J Endocrinol. 2024;2024:1785321. Published 2024Sep 14. doi:10.1155/2024/1785321 
5. Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775 
6. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028 
7. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831 
8. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221 
9. Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, Pinkerton JV. Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2016;101(4):1318-1343. doi:10.1210/jc.2016-1271 
10. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. Obstet Gynecol. 2023;142(5):1266-1273. doi:10.1097/AOG.0000000000005395 
11. Zhang Y, Chen G, Wang W, Yang D, Zhu D, Jing Y. Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials. Bone. 2025;192:117338. doi:10.1016/j.bone.2024.117338 
12. Cheng L, Hu Y, Li YY, et al. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2019;35(7):e3168. doi:10.1002/dmrr.3168 
13. Khor W, Chi K, Lin H, Chang Y. Glucagon-Like Peptide 1 Receptor Agonist Use and Vertebral Fracture Risk in Type 2 Diabetes. JAMA Surg. 2026;161(2):197-199. doi:10.1001/jamasurg.2025.5372 
14. Kasher Meron M, Hornik-Lurie T, Twig G, Rotman-Pikielny P. GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes. J Clin Endocrinol Metab. Published online February 10, 2026. doi:10.1210/clinem/dgag056 
15. Luo G, Liu H, Lu H. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? Br J Clin Pharmacol. 2016;81(1):78-88. doi:10.1111/bcp.12777 
16. American Diabetes Association Professional Practice Committee for Diabetes. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S61-S88. doi:10.2337/dc26-S004 
17. US Preventive Services Task Force. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(17):1740-1746. doi:10.1001/jama.2022.18625